Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 27.11% | 29.40% | 33.64% | 45.96% | 35.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.55% | -8.50% | -11.52% | -3.03% | 37.41% |
| Operating Income | 5.55% | 8.50% | 11.52% | 3.03% | -37.41% |
| Income Before Tax | -2.17% | -4.84% | 15.33% | 11.02% | -7.85% |
| Income Tax Expenses | -73.63% | -71.98% | -100.97% | -95.05% | -- |
| Earnings from Continuing Operations | -2.07% | -4.74% | 15.44% | 11.12% | -7.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -92.84% | -88.58% | -83.37% | -67.53% | 4.70% |
| Net Income | -4.09% | -7.25% | 13.65% | 9.63% | -8.05% |
| EBIT | 5.55% | 8.50% | 11.52% | 3.03% | -37.41% |
| EBITDA | -17.81% | -14.59% | -12.32% | -23.58% | -37.50% |
| EPS Basic | -18.66% | -13.90% | 18.38% | 16.02% | 21.26% |
| Normalized Basic EPS | 10.08% | 12.18% | 37.55% | 34.38% | 21.37% |
| EPS Diluted | -19.53% | -14.76% | 17.71% | 15.34% | 21.26% |
| Normalized Diluted EPS | 10.08% | 12.18% | 37.55% | 34.38% | 21.37% |
| Average Basic Shares Outstanding | 13.19% | 21.84% | 37.55% | 40.55% | 40.32% |
| Average Diluted Shares Outstanding | 13.19% | 21.84% | 37.55% | 40.55% | 40.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |